CDEK
← All drugs Report issue

tabalumab

mAbexperimental

Tabalumab is an anti-B-cell activating factor (BAFF) human monoclonal antibody designed for the treatment of autoimmune diseases and B cell malignancies. Tabalumab was developed by Eli Lilly and Company. — Wikipedia

Clinical trial activity

21 trials · 2 clinical orgs · 0 marketing orgs

Phase 1
4
Phase 2
17
Phase 3
9
Phase 4
0

Earliest trial started Mar 1, 2006 (NCT00308282)

Timeline

2000s

  1. Jan 1, 2006

    Earliest Phase 2 Sponsor(trial)

  2. Jan 1, 2008

    Earliest Phase 1 Sponsor(trial)

2010s

  1. Jan 1, 2010

    Earliest Phase 3 Sponsor(trial)

Indications

Studied for

Mechanism of action

Chemistry & pharmacology

Chirality
Single Stereoisomer
Inorganic
No
Polymer
No
Multi-specific
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • ly2127399
  • ly-2127399
  • ly-2127399
  • tabalumab
  • tabalumab
  • tabalumab
  • tabalumab

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT02041091Phase 3Jan 1, 2014Eli Lilly
NCT01676701Phase 3Sep 1, 2012Eli Lilly
NCT01602224Phase 2Jul 1, 2012Eli Lilly
NCT01556438Phase 1Jul 1, 2012Eli Lilly
NCT01576549Phase 2May 1, 2012Eli Lilly
NCT01488708Phase 3Jan 1, 2012Eli Lilly
NCT01215942Phase 3Jun 1, 2011Eli Lilly
NCT01200290Phase 2Apr 1, 2011Eli Lilly
NCT01202773Phase 3Jan 1, 2011Eli Lilly
NCT01202760Phase 3Jan 1, 2011Eli Lilly
NCT01205438Phase 3Jan 1, 2011Eli Lilly
NCT01198002Phase 3Dec 1, 2010Eli Lilly
NCT01196091Phase 3Dec 1, 2010Eli Lilly
NCT01253291Phase 1May 1, 2010Eli Lilly
NCT01253226Phase 1Sep 1, 2009Eli Lilly
NCT00882999Phase 2Apr 1, 2009Eli Lilly
NCT00837811Phase 2Feb 1, 2009Eli Lilly
NCT00785928Phase 2Oct 1, 2008Eli Lilly
NCT00689728Phase 2Jun 1, 2008Eli Lilly
NCT00689507Phase 1Mar 1, 2008Applied Molecular Evolution, Eli Lilly
Showing 20 of 21 trials
Page 1 / 2

Organizations

Research & Development (2)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Eli LillyFor profit212032006
Applied Molecular EvolutionFor profit1112008
2 organizations
Page 1 / 1